000167995 001__ 167995
000167995 005__ 20260123152958.0
000167995 0247_ $$2doi$$a10.1007/s13105-025-01130-6
000167995 0248_ $$2sideral$$a147631
000167995 037__ $$aART-2025-147631
000167995 041__ $$aeng
000167995 100__ $$aAranaz, Paula
000167995 245__ $$aPreclinical research in obesity-associated metabolic diseases using in vitro, multicellular, and non-mammalian models
000167995 260__ $$c2025
000167995 5060_ $$aAccess copy available to the general public$$fUnrestricted
000167995 5203_ $$aAddressing the physiological effects of bioactive compounds in metabolic diseases (i.e., obesity, diabetes, liver steatosis) and establishing their mechanisms of action have been a major interest for the last decades. However, methodologies that can be applied to achieve this can vary greatly, leading to a limited type of information. Thus, the accuracy, robustness, reliability and potential (human) translation are highly reliant on the experimental design and selected methodological models. This review presents an update exploring the main features, advantages and disadvantages of most important pre-clinical models used at the present time to study the effects of bioactive compounds on metabolic diseases. Moreover, future challenges in developing new methods are also depicted. In vitro models (enzyme assays and standard two-dimensional cultures of adipocytes, skeletal muscle cells) are intrinsically well established and constitute the first choice and most widely used methods to study bioactive compounds in metabolic diseases. However, novel models such as three-dimensional cultures (spheroids, organoids) are also starting to emerge and complement traditional culture systems. Models of small organisms (C. elegans, D. melanogaster) and non-mammal vertebrates (D. rerio) represent a scientific advantage and a middle-step before traditional mammalian models (rats and mice). This article provides extensive information and a critical overview of a wide range of methods that represent present and future avenues towards a further understanding of metabolic diseases. Combining and developing new methods will be key for future progression on the effects of bioactive compounds on metabolic diseases, as well as to minimize the use of mammalian models due to ethical reasons
000167995 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000167995 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000167995 700__ $$aClavel-Millan, Marina
000167995 700__ $$aGil-Cardoso, Katherine
000167995 700__ $$aGonzález-Arceo, Maitane
000167995 700__ $$aHernández-González, David
000167995 700__ $$0(orcid)0000-0002-7972-7119$$aLes, Francisco
000167995 700__ $$aSalles, Jérôme
000167995 700__ $$aAmri, Ez-Zoubir
000167995 700__ $$0(orcid)0000-0002-8982-3737$$aArbones-Mainar, José M.
000167995 700__ $$aAtgié, Claude
000167995 700__ $$aCapel, Frédéric
000167995 700__ $$aCourtois, Arnaud
000167995 700__ $$aEscoté, Xavier
000167995 700__ $$aGarcía-Barrado, María José
000167995 700__ $$aKrisa, Stéphanie
000167995 700__ $$0(orcid)0000-0001-6969-1055$$aLópez, Víctor
000167995 700__ $$aMilagro, Fermín I.
000167995 700__ $$aPortillo, María P.
000167995 700__ $$0(orcid)0000-0002-1033-6152$$aLorente-Cebrián, Silvia$$uUniversidad de Zaragoza
000167995 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000167995 773__ $$g81, 4 (2025), 1225-1255$$pJ. physiol. biochem.$$tJournal of Physiology and Biochemistry$$x1138-7548
000167995 8564_ $$s2205249$$uhttps://zaguan.unizar.es/record/167995/files/texto_completo.pdf$$yVersión publicada
000167995 8564_ $$s2115129$$uhttps://zaguan.unizar.es/record/167995/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000167995 909CO $$ooai:zaguan.unizar.es:167995$$particulos$$pdriver
000167995 951__ $$a2026-01-23-14:33:03
000167995 980__ $$aARTICLE